Searchable abstracts of presentations at key conferences in endocrinology

ea0002p68 | Neuroendocrinology | SFE2001

SAFETY AND MORTALITY DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN 4457 ADULT GH-DEFICIENT PATIENTS - A KIMS DATABASE ANALYSIS

Monson J , Abs R , #B-A|#Bengstonn|# , Feldt-Rasmussen U , Goth M , Koltowska M , Mattsson A , Westberg B , Wilton P

This analysis is based on 4457 patients (2365 males, 2092 females; mean age 44 years, range 18-83) with severe GH deficiency (GHD) enrolled in KIMS (pharmaco-epidemiological survey of GH replacement in adult GH-deficient patients, sponsored by Pharmacia Corporation). The mean duration of adult GH replacement was 2.8 years (range 0.1-11.0) giving 10,779 patient years of follow up. The baseline prevalence of diabetes mellitus prior to GH replacement was 3.7 % (compared with popu...